VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2019 | Key challenges of using the intestinal microbiome as a biomarker

Melody Smith
EBMT 2019
Leukemia Lymphoma CAR-T

Here, Melody Smith, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, discusses the main challenges that are present when utilizing the intestinal microbiome as a biomarker. Dr Smith was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Melody Smith

0:58
The intestinal microbiome for evaluating patient response to CAR T-cell therapy
Melody Smith

Related Videos

1:32
CAR T-cell therapy: the importance of LTFU
Graham Collins
2:55
CD19 CAR T-cell therapy for lymphoma
Michael Schmitt
1:44
The future of AML therapy
Andreas Burchert
0:42
Treating pediatric patients with hematological malignancies
Claudia Rössig
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals